Vorifast 200mg Tablet

Interaction

Drug :- alfentanil: Increased plasma alfentanil level and increased risk of adverse reactions.

benzodiazepines: Possibly prolonged sedative effect of benzodiazepines.

calcium channel blockers, HMG-CoA reductase inhibitors, such as lovastatin, omeprazole, sirolimus: Possibly increased plasma levels of these drugs, leading to increased risk of adverse reactions and toxicity.

carbamazepine, long-acting barbiturates, phenytoin, rifampin: Decreased plasma voriconazole concentration.

coumarin, warfarin: Possibly increased PTT cyclosporine, sirolimus, tacrolimus: Increased serum concentrations of these drugs and risk of toxicity, especially nephrotoxicity.

CYP3A4 substrates astemizole, cisapride, pimozide, quinidine, terfenadine: Increased plasma levels of these drugs, which may lead to prolonged QT interval and, rarely, torsades de pointes.

ergot alkaloids ergotamine, dihydroergotamine: May increase plasma level of ergot alkaloids, leading to ergotism.

HIV protease inhibitors amprenavir, nelfinavir, ritonavir, saquinavir, non-nucleoside reverse transcriptase inhibitors delavirdine, efavirenz: Possibly inhibited metabolism of these drugs and voriconazole.

methadone: Increased plasma level of methadone, possibly leading to toxicity, including QT-interval prolongation.

oral contraceptives: Increased plasma voriconazole level and risk of toxicity.

rifabutin: Increased rifabutin plasma level, decreased voriconazole plasma level.

St. John's wort: Decreased plasma voriconazole level.

sulfonylureas: Possibly increased plasma level of sulfonylureas and increased risk of hypoglycemia.

vinca alkaloids: Possibly increased risk of neurotoxicity.